Martin Treder

Martin Treder has worked in the biotech industry since 2001. Martin began their career as Program Director at U3 Pharma AG, then moved to CT Atlantic AG in 2008 as Chief Scientific Officer. In 2015, they joined Affimed Therapeutics as Chief Scientific Officer, and in 2019 they became an Independent Biotech Consultant. In 2020, they were appointed Chief Scientific Officer at ARJUNA Therapeutics, and in 2022 they became Co-founding CSO and board member at LTZ Therapeutics.

Martin Treder attended Mazenod College before beginning their post-secondary education at Monash University, where they earned a B.Sc. (Hons) in 1993. Martin then attended The Julius Maximilians University of Würzburg and earned a Dipl. Biol. in 1996. Finally, they attended the Max-Planck Institute for Biochemistry, Martinsried, where they earned a Dr. rer. nat. in 2001.